Showing results (271-280 of 285) with videos related to

Sort By:
Pageof 29
The Lancet. Infectious Diseases|April 14, 2024
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trialKatrina M Pollock, Álvaro H Borges, Hannah M Cheeseman, et al.
Journal of Medicinal Chemistry|April 12, 2013
HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activityDenis R St Laurent, Michael H Serrano-Wu, Makonen Belema, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B InhibitorsKap-Sun Yeung, Brett R Beno, Kathy Mosure, et al.
Nature Communications|December 7, 2025
Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infectionHelen R Wagstaffe, Ryan S Thwaites, Jasmin K Sidhu, et al.
Bioorganic & Medicinal Chemistry Letters|April 14, 2011
Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virusXiaofan Zheng, Thomas W Hudyma, Scott W Martin, et al.
Patterns (New York, N.Y.)|October 24, 2022
SELFIES and the future of molecular string representationsMario Krenn, Qianxiang Ai, Senja Barthel, et al.
Medchemcomm|August 16, 2018
The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymeraseKyle J Eastman, Kyle Parcella, Kap-Sun Yeung, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Medical Image Analysis|June 14, 2024
The STOIC2021 COVID-19 AI challenge: Applying reusable training methodologies to private dataLuuk H Boulogne, Julian Lorenz, Daniel Kienzle, et al.
Journal of Medicinal Chemistry|April 22, 2017
Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical StudiesKap-Sun Yeung, Brett R Beno, Kyle Parcella, et al.
Pageof 29